Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV's focus on developing gene therapies for severe genetic conditions, particularly in hemophilia, Huntington's disease, and cardiovascular diseases, positions the company favorably within the biopharmaceutical sector. The recent encouraging data from Phase 1/2 studies of AMT-130 demonstrated exceptional efficacy and a strong biomarker profile, reinforcing its potential despite recent regulatory challenges, which management believes stem from process rather than data concerns. Furthermore, positive feedback from the FDA regarding the accelerated approval pathway and the lack of new safety or manufacturing issues strengthens uniQure's long-term outlook and enhances investor confidence in its innovative gene therapy pipeline.

Bears say

The negative outlook on uniQure NV's stock is primarily influenced by the likelihood of significant delays in the Biologics License Application (BLA) process for its candidate AMT-130, following the withdrawal of management's previous guidance for a submission in 1Q26. Additionally, the absence of any revenue-generating products, coupled with ongoing financial losses since the firm's inception, exacerbates concerns regarding its fiscal stability and operational viability. Lastly, increasing market competition from existing therapies presents a substantial risk to uniQure's potential market penetration and pricing strategy, further complicating its path to profitability.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.